Key result
Multi-Link Frontier bifurcation stent yields a ~17% 6-month major cardiovascular events rate with 93% procedural success.
Why the study?
The treatment of coronary bifurcation lesions remains challenging, motivating evaluation of the safety and performance of the novel Multi-Link Frontier dedicated coronary bifurcation stent system.
What is the safety and performance of the Multi-Link Frontier coronary bifurcation stent system in reducing 180-day MACE in patients with coronary bifurcation lesions?
Cohort (n=105)
Yes
What is the safety and performance of the Multi-Link Frontier coronary bifurcation stent system in reducing 180-day MACE in patients with coronary bifurcation lesions?
The dedicated Multi-Link Frontier bifurcation stent system demonstrated a 91% implantation success rate and a 17.1% 6-month MACE rate, though overall branch angiographic restenosis reached 44.8%.
Answers are grounded in this paper and cite their sources.
Supports feasibility in complex bifurcations; leaves open randomized comparison to provisional stenting for restenosis and outcomes.
Objectives The goal of this study was to evaluate the safety and performance of the Multi-Link Frontier coronary bifurcation stent system (Guidant Corp., Santa Clara, California), a novel dedicated device designed for permanent side branch (SB) access, stent delivery by simultaneous kissing balloon inflation, and optimal main branch (MB) and SB ostium scaffolding. Background The treatment of coronary bifurcation lesions remains challenging, and various approaches using stents have been proposed. Methods The primary end point was the 180-day incidence of major adverse cardiac events (MACE) per intent-to-treat analysis. Secondary end points included device success, 30-day MACE, angiographic restenosis, and target lesion revascularization (TLR) rates at 180 days. Results After a learning phase of two cases per center, 105 patients were prospectively included in 11 centers. The left anterior descending coronary artery/diagonal bifurcation was the target in 80% of cases. The Frontier stent was successfully implanted in 96 patients (91%), and procedural success was obtained in 93%. Two patients suffered in-hospital myocardial infarction (MI) secondary to SB occlusion, and one patient underwent elective coronary artery bypass grafting. At 30 days and 6 months, the MACE rates were 2.9% and 17.1% (no death, no subacute stent thrombosis, Q-wave MI 1.0% and 1.9%, non-Q-wave MI 1.0% and 1.9%, TLR 1.0% and 13.3%). The MB in-stent restenosis was 25.3%, in-segment 29.9%. The SB restenosis was 29.1%. The overall restenosis rate for any branch was 44.8%. Conclusions The results of this Frontier registry demonstrate the safety and performance of this dedicated stent system for the treatment of bifurcation lesions. The device can be successfully implanted in more than 90% of all cases, with a high procedural success rate and low 30-day and 6-month MACE rates.
No takes yet. Share an insight, caveat, or question.
Lefèvre et al. (2005) conducted a cohort in Coronary bifurcation lesions (n=105). Multi-Link Frontier coronary bifurcation stent system was evaluated on 180-day incidence of major adverse cardiac events (MACE) per intent-to-treat analysis. The Multi-Link Frontier bifurcation stent system achieved 91% successful implantation, 93% procedural success, and a 17.1% major cardiovascular events rate at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: